LOGIN  |  REGISTER
Recursion
C4 Therapeutics

I-Mab to Participate at the Jefferies Global Healthcare Conference

May 22, 2024 | Last Trade: US$4.64 0.00 0.00

ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.

Jefferies Global Healthcare Conference

Presentation Time

Wednesday, June 5 at 9:30 a.m. EST

Presenters

Raj Kannan, CEO; Louie Naumovski, Interim CMO

Webcast link

Here

Meetings

One-on-one and small group meetings: June 5, 2024

Management
Participants

Raj Kannan, CEO

Joe Skelton, CFO

Louie Naumovski, Interim CMO

Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website at https://ir.i-mabbiopharma.com/

For more information, please contact your Jefferies representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit  https://ir.i-mabbiopharma.com/ and follow us on LinkedIn and X.

For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page